Increasing Use of Continuous Glucose Monitors in Publicly-insured Youth With Type 1 Diabetes

Improving Adherence to Continuous Glucose Monitors in Publicly-insured Youth With Type 1 Diabetes

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03297762

Enrollment

Registered

2017-09-29

Start date

2018-05-07

Completion date

2019-06-01

Last updated

2020-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type1diabetes

Brief summary

To use an enhanced continuous glucose monitor (CGM) experience, including an automated CGM-electronic health record (EHR) data integration system, proactive interventions, and gamification techniques, to increase CGM use among publicly-insured youth with type 1 diabetes (T1D).

Detailed description

The investigators will use an automated data integration system to monitor hours per week the CGM is worn and target interventions/troubleshooting techniques as needed. The investigators will use gamification techniques (i.e. ability to gain points and achieve small rewards) to help encourage CGM use and potentially improve glycemic control in this at-risk population.

Interventions

BEHAVIORALUse of Dexcom G5

Dexcom G5 continuous glucose monitor

BEHAVIORALgamification

incentives/rewards and contact between standard visits

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

13 Years to 19 Years

Healthy volunteers

Inclusion criteria

* type 1 diabetes for more than 6 months * on insulin pump or multiple daily injections without plans to change modality in next 6 months * insured by CCS or Medi-Cal * receiving care at Lucile Packard Children's Hospital or Stanford Children's Health outpatient clinics * English or Spanish-speaking

Exclusion criteria

* major illness or condition that may alter glucose control or ability to complete the study including pregnancy, cystic fibrosis, cancer, liver disease, history of transplant, or hemoglobinopathy * current oral glucocorticoid use * prior use of a CGM system * hemoglobin A1C \<7.5% or \>12% * no wireless internet access

Design outcomes

Primary

Measure	Time frame	Description
CGM use	baseline to 6 months	amount of time per week CGM is used

Secondary

Measure	Time frame	Description
Hgb A1c	baseline to 6 months	glycemic control as measured by Hgb A1c

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026